Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $9.29M
• Dividend Yield: N/A
• Average Volume (3M): 14.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -62.68%
• EPS Growth: 23.94%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -4.46
• Shares Outstanding: 1,919,441
• 10 Day Avg. Volume: 9,366
• 30 Day Avg. Volume: 14,092
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -0.01
• Enterprise Value/Gross Profit: -0.02
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $40.50
• Price Target Upside: 680.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 52 Neutral
• Price Target: $7.00 ▲(34.87% Upside)

Bolt Biotherapeutics exhibits financial instability with persistent losses and negative cash flow, impacting its financial performance score. Technical indicators offer some stability but lack strong momentum. The valuation is constrained by the negative P/E ratio, reflecting the challenges the company faces in achieving profitability.

Positive Factors

Clinical Trials

BDC-4182 outperformed other cytotoxic claudin 18.2 ADCs in preclinical models, suggesting potential competitiveness in the market.

Partnership Opportunities

There is a reasonable likelihood that Bolt successfully out-licenses the asset in the coming months.

Negative Factors

Financial Stability

There is uncertainty whether Bolt secures attractive enough economic terms to meaningfully extend their cash runway beyond mid-2026.

Market Competition

Several peer companies have ongoing or discontinued programs targeting CLDN18.2, indicating a competitive landscape for Bolt Biotherapeutics.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary immune-oncology therapies. The company generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies that provide funding for research and development in exchange for rights to commercialize successful therapies. Additionally, Bolt Biotherapeutics may receive milestone payments and royalties from these partners based on the achievement of certain clinical, regulatory, and sales milestones. The company's financial sustainability is highly dependent on the successful advancement of its clinical pipeline and its ability to establish and maintain strategic alliances in the competitive biotechnology space.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics faces significant profitability challenges despite modest revenue growth and a stable gross profit margin. The company has a low debt-to-equity ratio, indicating conservative leverage, but continues to struggle with negative cash flow and return on equity.

Income Statement

Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.

Cash Flow

Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.26M	7.69M	7.88M	5.73M	1.26M	231.00K
Gross Profit	12.37M	5.51M	5.99M	838.00K	-2.41M	-40.13M
EBITDA	-52.09M	-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
Net Income	-50.71M	-63.12M	-69.20M	-85.88M	-104.39M	-72.27M
Balance Sheet
Total Assets	75.50M	99.63M	159.78M	227.81M	307.72M	46.54M
Cash, Cash Equivalents and Short-Term Investments	34.77M	47.32M	102.19M	168.89M	186.22M	22.84M
Total Debt	24.18M	25.21M	20.22M	22.61M	24.36M	10.88M
Total Liabilities	36.66M	42.43M	47.04M	56.30M	57.60M	151.49M
Stockholders Equity	38.84M	57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow
Free Cash Flow	-51.40M	-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
Operating Cash Flow	-51.36M	-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
Investing Cash Flow	54.71M	57.58M	71.04M	57.86M	-232.20M	-20.59M
Financing Cash Flow	43.00K	108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 5.20, below the 50-day MA of 5.63, and below the 200-day MA of 7.99, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 46.63 is Neutral, neither overbought nor oversold. The STOCH value of 34.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$9.29M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
BRTX	48 Neutral	$13.00M	―	-137.09%	―	247.62%	-7.66%
CRIS	42 Neutral	$21.37M	―	-2951.24%	―	12.24%	40.74%
MEIP	41 Neutral	$140.22M	―	-89.73%	―	-100.00%	-221.06%
CLRB	34 Underperform	$15.90M	―	-273.88%	―	―	73.37%
INAB	34 Underperform	$9.90M	―	-165.56%	―	―	58.67%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics Announces Reverse Stock Split

On June 6, 2025, Bolt Biotherapeutics implemented a one-for-twenty reverse stock split of its common stock, following approval from stockholders and the Board of Directors on May 27, 2025. This move affects the company’s outstanding shares, equity incentive plans, and stock options, with trading on a split-adjusted basis set to begin on June 9, 2025, on the Nasdaq Capital Market under the ticker ‘BOLT’.